HighTide Therapeutics, Inc. (“HighTide”) was invited to present at the Office for Attracting Strategic Enterprises (OASES) launching ceremony hosted by the Hong Kong government. HighTide, a company focused on the discovery and development of first-in-class multifunctional therapies for diseases with significant unmet medical needs, has conducted 11 clinical trials in multiple countries and holds numerous patents granted globally. HighTide was recognized by the Hong Kong government through this strategic enterprise partner.

Mr. John Lee, Chief Executive of the Government of the Hong Kong Special Administrative Region (HKSAR) of China announced in his Policy Address in October 2022 that the Government would establish OASES for attracting high potential and representative strategic enterprises from around the globe. At the OASES partnership launch ceremony witnessed by the Chief Executive, Mr. John Lee; the Financial Secretary, Mr. Paul Chan and senior government officials, industry leaders and experts. The HKSAR Government attaches great importance to high-potential key enterprises, especially in the fields of life and health technology, artificial intelligence and data science, financial technology as well as advanced manufacturing and new-energy technology. As one of the representatives of strategic enterprise at the ceremony, HighTide is regarded by the Hong Kong government as a potential biomedical enterprise. OASES will provide one-stop services to HighTide and support the company’s development and specific needs in Hong Kong. HighTide will also explore more collaborative opportunities to promote the development of Hong Kong's innovation and technology (I&T) ecosystem.

HighTide will actively contribute to the economic development of Hong Kong as a representative of strategic enterprise. HighTide has established operations in the Hong Kong Science Park, which will serve as the hub for HighTide's global business development. HighTide is also conducting clinical research for core product berberine ursodeoxycholate (HTD1801) and plans to introduce the FUSIONTX™ drug development approach  and establish a research and development center for innovative products in Hong Kong. These initiatives will additionally bolster product iterations and innovative project developments, thus amplifying the diversity and global competitiveness of Hong Kong's biotechnology sector in the future. Aside from expediting the globalization and commercialization of its current product pipeline, HighTide will utilize its extensive expertise in drug development to actively engage with the government, industry, academia, research institutions, and the capital markets. This will be a real boost to the development of innovative life sciences in Hong Kong.

About HighTide Therapeutics
HighTide Therapeutics, Inc. is a globally integrated biopharmaceutical company focusing on the discovery and development of first-in-class multifunctional multi-targeted therapies with poly-indications across metabolic and digestive diseases with significant unmet medical needs. The company is developing multiple clinical assets, including therapy for nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2DM), severe hypertriglyceridemia (SHTG), primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC). Berberine ursodeoxycholate (HTD1801), the company’s lead drug candidate, received Fast Track designation from the U.S. FDA for both NASH and PSC, as well as Orphan Drug designation for PSC. In China, HTD1801 has been included in the National Major New Drug Innovation Program under the 13th Five-Year Plan for Major Technology Project.

Disclaimer
The information contained herein is based solely on events or data available as of the date of this document. Unless required by law, we are under no obligation to update or publicly revise any forward-looking statements or events beyond those anticipated, even if new information, future events, or other circumstances arise after the date of the forward-looking statement. Please review this document carefully and be aware that our actual future performance or results may significantly deviate from expectations. All statements in this document are made as of the publication date and may change in light of future developments.

For more information, please visit www.hightidetx.com.
Contact: pr@hightidetx.com